Spinal Cord Injury News and Research

RSS
A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.
Researchers recommend traumatic brain injury reclassification for additional funding

Researchers recommend traumatic brain injury reclassification for additional funding

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Abilities Expo to be held August 27-29, 2010 in Houston, Texas

Abilities Expo to be held August 27-29, 2010 in Houston, Texas

FRC applauds preliminary injunction to stop taxpayers for embryonic stem cell research

FRC applauds preliminary injunction to stop taxpayers for embryonic stem cell research

Human neural stem cells restore motor function in mice with chronic spinal cord injury

Human neural stem cells restore motor function in mice with chronic spinal cord injury

UCI study is first to show reversal of long-term hind-limb paralysis

UCI study is first to show reversal of long-term hind-limb paralysis

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

NACTN receives grant to expand spinal cord injury research

NACTN receives grant to expand spinal cord injury research

StemCells second-quarter net loss decreases to $4.61 million

StemCells second-quarter net loss decreases to $4.61 million

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

RNL BIO research identifies adult stem cell's ability to inhibit cancer

RNL BIO research identifies adult stem cell's ability to inhibit cancer

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Myths and realities of Medicare bidding program for durable medical equipment

Myths and realities of Medicare bidding program for durable medical equipment

TCA Cellular Therapy enrolls first patient for adult stem cell clinical trial

TCA Cellular Therapy enrolls first patient for adult stem cell clinical trial

Acorda second-quarter net loss decreases to $6.8 million

Acorda second-quarter net loss decreases to $6.8 million

Healthsouth Corporation experiences positive trends in second quarter

Healthsouth Corporation experiences positive trends in second quarter

Inpatient rehab helps patient to regain functions lost from injury, illness

Inpatient rehab helps patient to regain functions lost from injury, illness

HealthSouth plans new rehabilitation hospital in northwest Houston

HealthSouth plans new rehabilitation hospital in northwest Houston

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.